EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Dr Faith Davies, NYU Langone Hospital, New York, USA, explains in this video the pre-clinical myeloma updates presented in the American Society of Hematology (ASH) Annual Meeting 2019 and why are those important to patients.
Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important updates…
Real World Evidence (RWE) is becoming more and more important not only for clinicians but also for scientific meetings such as the American Society of Hematology (ASH) Annual Meeting. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important updates regarding Real World Evidence in myeloma presented at ASH 2019.
Minimal Residual Disease (MRD) is one of the big topics in myeloma. Different techniques to measure MRD and new data about its role in predicting the risk of relapse are some of the topics discussed during the American Society of Hematology (ASH) Annual Meeting. In this video Dr Francesca Gay, University of Torino, Italy, explains for Myeloma Patients Europe (MPE) what was presented at ASH 2019 regarding MRD and the unanswered questions about its role…
More than 900 myeloma abstracts (posters and oral sessions) were presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that was held from 7 to 10 December 2019 in Orlando, Florida, USA. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important myeloma updates presented at ASH 2019.
Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel) summarised for Myeloma Patients Europe (MPE) the main updates on AL amyloidosis presented at the American Society of Hematology (ASH) Annual Meeting held from 7 to 10 December 2019 in Orlando, Florida, USA.
The European Society for Medical Oncology (ESMO) Annual Congress was held from 27 September to 1 October 2019 in Barcelona, Spain.
MPE held a webinar on personalised medicines in myeloma with the aim of providing an overview of how haematologists adapt treatment to each patient and to discuss the barriers healthcare systems have to face. The talk was given by Dr Annemiek Broijl, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
MPE held a webinar on CAR-T cell treatment with the aim of providing an overview of CAR-T cell treatment in myeloma and to discuss some of the advantages and challenges the myeloma community faces in bringing this treatment to market.
